Skip to main content
NCBI home page
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
editorial
. 1996 Jan 1;154(1):49–53.

Habit, prejudice, power and politics: issues in the conversion of H2-receptor antagonists to over-the-counter use.

R H Hunt
PMCID: PMC1488093  PMID: 8542566

Abstract

H2-receptor antagonists have been widely prescribed in the last 20 years and are considered to rank among the safest drugs known. In several countries they have been switched to over-the-counter (OTC) status, and a similar move is under consideration in Canada. Some concerns have been raised as to the effectiveness of these drugs in the treatment of dyspepsia and heartburn, their safety when taken for self-diagnosed symptoms, and the potential for their use to delay diagnosis or mask serious disease. The author presents evidence to support the use of OTC H2-receptor antagonists in the treatment of dyspepsia. He argues that the safety record of these drugs is reassuring and that they are unlikely to mask gastric cancer. Finally, he describes the appropriate place of OTC H2-receptor antagonists in the overall management of acid-related disorders.

Full text

PDF
49

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersen M., Schou J. S. Adverse reactions to H2-receptor antagonists in Denmark before and after transfer of cimetidine and ranitidine to over-the-counter status. Pharmacol Toxicol. 1991 Oct;69(4):253–258. doi: 10.1111/bcpt.1991.69.4.253. [DOI] [PubMed] [Google Scholar]
  2. Andersen M., Schou J. S. Are H2 receptor antagonists safe over the counter drugs? BMJ. 1994 Aug 20;309(6953):493–494. doi: 10.1136/bmj.309.6953.493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Andersen M., Schou J. S. Safety implications of the over-the-counter availability of H2-antagonists. Drug Saf. 1993 Mar;8(3):179–185. doi: 10.2165/00002018-199308030-00001. [DOI] [PubMed] [Google Scholar]
  4. Bennett E., Beaurepaire J., Langeluddecke P., Kellow J., Tennant C. Life stress and non-ulcer dyspepsia: a case-control study. J Psychosom Res. 1991;35(4-5):579–590. doi: 10.1016/0022-3999(91)90052-p. [DOI] [PubMed] [Google Scholar]
  5. Bernersen B., Johnsen R., Bostad L., Straume B., Sommer A. I., Burhol P. G. Is Helicobacter pylori the cause of dyspepsia? BMJ. 1992 May 16;304(6837):1276–1279. doi: 10.1136/bmj.304.6837.1276. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Colin-Jones D. G., Langman M. J., Lawson D. H., Vessey M. P. Cimetidine and gastric cancer: preliminary report from post-marketing surveillance study. Br Med J (Clin Res Ed) 1982 Nov 6;285(6351):1311–1313. doi: 10.1136/bmj.285.6351.1311. [DOI] [PubMed] [Google Scholar]
  7. Colin-Jones D. G., Langman M. J., Lawson D. H., Vessey M. P. Postmarketing surveillance of the safety of cimetidine: mortality during second, third, and fourth years of follow up. Br Med J (Clin Res Ed) 1985 Oct 19;291(6502):1084–1088. doi: 10.1136/bmj.291.6502.1084. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Colin-Jones D. G. When should endoscopy (or radiology) be used in dyspepsia and peptic ulcer disease? Aliment Pharmacol Ther. 1987;1 (Suppl 1):548S–555S. doi: 10.1111/j.1365-2036.1987.tb00664.x. [DOI] [PubMed] [Google Scholar]
  9. Feldman M., Burton M. E. Histamine2-receptor antagonists. Standard therapy for acid-peptic diseases (2) N Engl J Med. 1990 Dec 20;323(25):1749–1755. doi: 10.1056/NEJM199012203232507. [DOI] [PubMed] [Google Scholar]
  10. Feldman M. Pros and cons of over-the-counter availability of histamine2-receptor antagonists. Arch Intern Med. 1993 Nov 8;153(21):2415–2424. [PubMed] [Google Scholar]
  11. Gotthard R., Bodemar G., Brodin U., Jönsson K. A. Treatment with cimetidine, antacid, or placebo in patients with dyspepsia of unknown origin. Scand J Gastroenterol. 1988 Jan;23(1):7–18. doi: 10.3109/00365528809093840. [DOI] [PubMed] [Google Scholar]
  12. Holt S. Over-the-counter histamine H2-receptor antagonists. How will they affect the treatment of acid-related diseases? Drugs. 1994 Jan;47(1):1–11. doi: 10.2165/00003495-199447010-00001. [DOI] [PubMed] [Google Scholar]
  13. Jan L. Y., Jan Y. N. Voltage-sensitive ion channels. Cell. 1989 Jan 13;56(1):13–25. doi: 10.1016/0092-8674(89)90979-3. [DOI] [PubMed] [Google Scholar]
  14. Johannessen T., Fjøsne U., Kleveland P. M., Halvorsen T., Kristensen P., Løge I., Hafstad P. E., Sandbakken P., Petersen H. Cimetidine responders in non-ulcer dyspepsia. Scand J Gastroenterol. 1988 Apr;23(3):327–336. doi: 10.3109/00365528809093874. [DOI] [PubMed] [Google Scholar]
  15. Jones R., Lydeard S. Dyspepsia in the community: a follow-up study. Br J Clin Pract. 1992 Summer;46(2):95–97. [PubMed] [Google Scholar]
  16. Jones R., Lydeard S. Prevalence of symptoms of dyspepsia in the community. BMJ. 1989 Jan 7;298(6665):30–32. doi: 10.1136/bmj.298.6665.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kay L., Jørgensen T. Epidemiology of upper dyspepsia in a random population. Prevalence, incidence, natural history, and risk factors. Scand J Gastroenterol. 1994 Jan;29(1):2–6. [PubMed] [Google Scholar]
  18. Mackinnon M., Willing R. L., Whitehead R. Cimetidine in the management of symptomatic patients with duodenitis: a double-blind controlled trial. Dig Dis Sci. 1982 Mar;27(3):217–219. doi: 10.1007/BF01296918. [DOI] [PubMed] [Google Scholar]
  19. Management of dyspepsia: report of a working party. Lancet. 1988 Mar 12;1(8585):576–579. [PubMed] [Google Scholar]
  20. Morgan P. P., Cohen L. Off the prescription pad and over the counter: the trend toward drug deregulation grows. CMAJ. 1995 Feb 1;152(3):387–389. [PMC free article] [PubMed] [Google Scholar]
  21. Nesland A. A., Berstad A. Effect of cimetidine in patients with non-ulcer dyspepsia and erosive prepyloric changes. Scand J Gastroenterol. 1985 Jun;20(5):629–635. doi: 10.3109/00365528509089708. [DOI] [PubMed] [Google Scholar]
  22. Oster G., Huse D. M., Delea T. E., Colditz G. A., Richter J. M. The risks and benefits of an Rx-to-OTC switch. The case of over-the-counter H2-blockers. Med Care. 1990 Sep;28(9):834–852. doi: 10.1097/00005650-199009000-00012. [DOI] [PubMed] [Google Scholar]
  23. Rios-Castellanos E., Sitas F., Shepherd N. A., Jewell D. P. Changing pattern of gastric cancer in Oxfordshire. Gut. 1992 Oct;33(10):1312–1317. doi: 10.1136/gut.33.10.1312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Schiller L. R., Fordtran J. S. Ulcer complications during short-term therapy of duodenal ulcer with active agents and placebo. Gastroenterology. 1986 Feb;90(2):478–481. doi: 10.1016/0016-5085(86)90950-9. [DOI] [PubMed] [Google Scholar]
  25. Schumacher M. C., Jick S. S., Jick H., Feld A. D. Cimetidine use and gastric cancer. Epidemiology. 1990 May;1(3):251–254. doi: 10.1097/00001648-199005000-00012. [DOI] [PubMed] [Google Scholar]
  26. Simon Thomas J., Berlin Roger G., Gardner Andrea H., Stauffer Laura A., Gould A. Lawrence, Getson Albert J. Self-Directed Treatment of Intermittent Heartburn: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Evaluation of Antacid and Low Doses of an H(2)-Receptor Antagonist (Famotidine). Am J Ther. 1995 May;2(5):304–313. [PubMed] [Google Scholar]
  27. Singal A. K., Kumar A., Broor S. L. Cimetidine in the treatment of non-ulcer dyspepsia: results of a randomized double-blind, placebo-controlled study. Curr Med Res Opin. 1989;11(6):390–397. doi: 10.1185/03007998909110140. [DOI] [PubMed] [Google Scholar]
  28. Singh S., Richter J. E., Bradley L. A., Haile J. M. The symptom index. Differential usefulness in suspected acid-related complaints of heartburn and chest pain. Dig Dis Sci. 1993 Aug;38(8):1402–1408. doi: 10.1007/BF01308595. [DOI] [PubMed] [Google Scholar]
  29. Spencer J. A., Edwards C. Pharmacy beyond the dispensary: general practitioners' views. BMJ. 1992 Jun 27;304(6843):1670–1672. doi: 10.1136/bmj.304.6843.1670. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Sue-Ling H. M., Martin I., Griffith J., Ward D. C., Quirke P., Dixon M. F., Axon A. T., McMahon M. J., Johnston D. Early gastric cancer: 46 cases treated in one surgical department. Gut. 1992 Oct;33(10):1318–1322. doi: 10.1136/gut.33.10.1318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Talley N. J., Fett S. L., Zinsmeister A. R., Melton L. J., 3rd Gastrointestinal tract symptoms and self-reported abuse: a population-based study. Gastroenterology. 1994 Oct;107(4):1040–1049. doi: 10.1016/0016-5085(94)90228-3. [DOI] [PubMed] [Google Scholar]
  32. Talley N. J., McNeil D., Hayden A., Piper D. W. Randomized, double-blind, placebo-controlled crossover trial of cimetidine and pirenzepine in nonulcer dyspepsia. Gastroenterology. 1986 Jul;91(1):149–156. doi: 10.1016/0016-5085(86)90451-8. [DOI] [PubMed] [Google Scholar]

Articles from CMAJ: Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES